title: CA-125 monitored therapy with GnRH analogue of pelvic endometriosis.
abstract: Thirteen patients affected by endometriosis have been treated with GnRH analogue Buserelin. CA-125 serum levels have been monitored before, during and after treatment. Analysis of data suggests the hypothesis of an individualized follow up by means of repeated assays of CA-125 and their reference to pre and post treatment graphs.
authors.affiliation: Clinica Ostetrica e Ginecologica, Università di Ferrara.
authors.forename: P
authors.initials: P
authors.lastname: Negri
authors.forename: M A
authors.initials: MA
authors.lastname: Ricciardelli
authors.forename: A
authors.initials: A
authors.lastname: Tomasi
authors.forename: E
authors.initials: E
authors.lastname: Grechi
authors.forename: R M
authors.initials: RM
authors.lastname: Fortini
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D002064:Buserelin / Q000009:adverse effects / Q000627:therapeutic use*; D004715:Endometriosis / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008597:Menstrual Cycle / Q000378:metabolism; D010386:Pelvic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D011374:Progesterone / Q000097:blood
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin